# Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

> **NCT00130442** · PHASE2 · COMPLETED · sponsor: **Cellxpert Biotechnology Corp.** · enrollment: 134 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** PI-88 and dacarbazine
- **DRUG:** dacarbazine or DTIC

## Key facts

- **NCT ID:** NCT00130442
- **Lead sponsor:** Cellxpert Biotechnology Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2022-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130442, "Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00130442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*